Measuring response in a post-RECIST world: from black and white to shades of grey

Nature Reviews. Cancer
Laura C Michaelis, Mark J Ratain

Abstract

The unprecedented pace of therapeutic development in oncology has created a climate in which the traditional methods of evaluating agent activity might no longer be adequate. How is the field transitioning to new endpoints in early drug development and what are the difficulties in this transition? Here, we will explore the historical context for the current criteria for tumour response evaluation and some of the pitfalls in using these standards when testing newer anticancer agents for activity. We will argue that the current drug development environment dictates different outcome measurements and therefore more imaginative and rigorous early-phase trial designs.

References

Nov 29, 1965·JAMA : the Journal of the American Medical Association·J Gurland, R O Johnson
Jan 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I Tannock, K Murphy
Jan 1, 1981·Cancer·A B MillerA Winkler
Mar 24, 1999·Journal of the National Cancer Institute·K JamesP Therasse
Oct 9, 2002·Current Pharmaceutical Design·Scott Wilhelm, Du-Shieng Chien
Oct 29, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P Therasse, UNKNOWN European Organisation for Research and Treatment of Cancer Data Center
Oct 29, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W R Parulekar, E A Eisenhauer
Nov 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary L RosnerMark J Ratain
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Sep 18, 2003·Journal of the National Cancer Institute·Stephen L George
May 1, 1963·American Journal of Surgery·A GILMAN
Sep 27, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas G RobertsBruce A Chabner
Jul 2, 2004·Nature Biotechnology·George S Mack
Oct 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark J Ratain, S Gail Eckhardt
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk StrumbergSiegfried Seeber
Jun 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Walter M StadlerMark J Ratain
Jul 27, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David R Gandara, Paul H Gumerlock
Aug 24, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mark J Ratain
Sep 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohammad I ZiaEric X Chen
Sep 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lawrence V RubinsteinMalcolm A Smith
Apr 26, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark J RatainPeter J O'Dwyer

❮ Previous
Next ❯

Citations

Apr 9, 2013·Journal of Pharmacokinetics and Pharmacodynamics·Michael Ingrisch, Steven Sourbron
Jan 19, 2008·Nature Reviews. Cancer·Kevin Brindle
Oct 7, 2010·Nature Reviews. Clinical Oncology·Bruno MorganRicky A Sharma
Feb 15, 2012·Nature Reviews. Clinical Oncology·James P B O'ConnorGordon C Jayson
Mar 14, 2008·Proceedings of the National Academy of Sciences of the United States of America·Amin HajitouWadih Arap
Feb 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·F Stephen HodiGlenn Dranoff
Apr 23, 2009·Journal of Biopharmaceutical Statistics·Ying Kuen Cheung
Jun 6, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W R JarnaginN Kemeny
Oct 17, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B CwiklaJ Walecki
Nov 13, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Z E LabbyS G Armato
Sep 10, 2010·Journal of the National Cancer Institute·Axel HoosJedd Wolchok
Jul 10, 2009·Current Opinion in Hematology·Markus KappGötz Ulrich Grigoleit
Oct 15, 2009·The Cancer Journal·Xavier PivotFernando Bazan
Nov 23, 2006·Cancer Imaging : the Official Publication of the International Cancer Imaging Society·S D CurranL H Schwartz
Nov 26, 2008·Cancer Imaging : the Official Publication of the International Cancer Imaging Society·Fiona Kyle, James Spicer
Oct 1, 2010·Cancer Imaging : the Official Publication of the International Cancer Imaging Society·P Murphy, D-M Koh
Jun 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rajul K JainRazelle Kurzrock
May 6, 2009·The AAPS Journal·Eric D Agdeppa, Mary E Spilker
Feb 14, 2013·The AAPS Journal·Ahmed Abbas SuleimanUwe Fuhr
Jun 24, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Richard L WahlMartin A Lodge
Mar 27, 2007·Future Oncology·Norbert Avril, David Propper
Aug 13, 2014·Nature Reviews. Clinical Oncology·Kyrre E EmblemRakesh K Jain
Nov 19, 2011·Current Oncology Reports·Alessandra GennariAndrea De Censi
Jan 23, 2008·Acta Oncologica·Peter NygrenGunnar Aström
Oct 1, 2014·Cancers·Andrea GallaminiAnna Borra
Nov 5, 2011·Expert Review of Anticancer Therapy·Enrico FranceschiAlba A Brandes
Aug 10, 2007·Expert Opinion on Investigational Drugs·Sergiusz Nawrocki, Andrzej Mackiewicz
Mar 22, 2012·Acta Oncologica·Kristin SkougaardHelle Hjorth Johannesen
Mar 15, 2013·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Zacariah E LabbyAnna K Nowak
Sep 17, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Ahmed Abbas SuleimanUwe Fuhr
Oct 13, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Zacariah E LabbyAnna K Nowak
Dec 18, 2008·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·Avo ArtinyanLawrence Wagman
Jul 6, 2011·Seminars in Roentgenology·Eithne Delappe, Mark Dunphy
Oct 26, 2010·Transplantation Proceedings·J Mackiewicz, A Mackiewicz
Jun 29, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sabrina AllegroSébastien J Hotte

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
E A EisenhauerJ Verweij
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Jeffrey L EvelhochJohn C Waterton
© 2022 Meta ULC. All rights reserved